Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EU Reforms Include ‘Prudent-Use’ Targets For Cuts To Antibiotic Consumption

Executive Summary

The European Commission says at least 65% of all human consumption of antibiotics should be of products that come under the World Health Organization’s AWaRe (Access, Watch, Reserve) classification, which have a lower risk of resistance.

You may also be interested in...



EU Working With Pharma Firms On Meeting Antibiotic Demand

A key meeting of stakeholders is to be held on 20 July to look at how best to avoid shortages of antibiotics for respiratory infections in Europe. 

EU Ministers Endorse ‘Multi-Country Pull Incentive’ For New Antimicrobial R&D

Although it is not legally binding, a recommendation endorsed this week by the Council of the EU will give countries more tools to tackle the thorny problem of resistance to antimicrobial drugs, according to the Swedish presidency of the council.

European Parliament Wants EU-Wide Pull Incentive Scheme For New Antimicrobials

The three major EU institutions are all calling for urgent action to tackle antimicrobial resistance, with the emphasis very much on incentives for the development of novel medicines and a reduction in overall consumption of antibiotics.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS148147

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel